ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of new cancer therapies. Its lead candidate, Palifosfamide (ZIO-201), a DNA alkylating agent, is under Phase III clinical trial for the treatment of first-line metastatic soft tissue sarcoma; and is in Phase III clinical trial for first-line metastatic small cell lung cancer. The company’s portfolio of clinical-stage product candidates also includes ZIN-CTI-001, which is in Phase Ib clinical trial in patients with metastatic melanoma; ZIN-ATI-001, which is in Phase 1b clinical trial in patients with late-stage melanoma; Indibulin (ZIO-301), a novel, tubulin binding agent in Phase I/II clinical trial in metastatic breast cancer; and Darinaparsin (ZIO-101), a novel mitochondrial-and hedgehog-targeted agent. In addition, it is developing oral capsule form of palifosfamide. The company has an exclusive channel partner agreement with Intrexon Corporation in which the company uses Intrexon Corporation technology directed towards in vivo expression of effectors in connection with the development of ZIN-CTI-001 and ZIN-ATI-001. ZIOPHARM Oncology, Inc. was founded in 2003 and is headquartered in New York, New York.

Key Statistics